Chronic Kidney Disease, Hemodialysis, Kidney Failure, Left Ventricular Hypertrophy
Conditions
Brief summary
change in Left Ventricular Mass indexed to body surface area (LVMI [g/m²]) from baseline to 6 months
Detailed description
Glucose Insulin C-Peptide Glucagon Glucagon-like Peptide-1 Epinephrine Norepinephrine Cortisol Growth Hormone Lactate Alanine β-hydroxybutyrate (βOHB) HbA1C Left Ventricular Mass (LVM) Left Ventricular Ejection Fraction (EF), Left Ventricular Hypertrophy (LVH) cardiac fibrosis Left Ventricular Mass Index to height(LVMI [m²]) Left Atrial Diameter (LAD [mm]) Blood Pressure (mmHg) Body Weight BMI Predialysis TnT postdialysis TnT proBNP Quality of Life
Interventions
DRUGForxiga 10 mg film-coated tablets
DRUGPlacebo identical to Forxiga 10mg encapsulated in Gelatinecapsules
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in Left Ventricular Mass indexed to body surface area (LVMI [g/m²]) from baseline to 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose Insulin C-Peptide Glucagon Glucagon-like Peptide-1 Epinephrine Norepinephrine Cortisol Growth Hormone Lactate Alanine β-hydroxybutyrate (βOHB) HbA1C Left Ventricular Mass (LVM) Left Ventricular Ejection Fraction (EF), Left Ventricular Hypertrophy (LVH) cardiac fibrosis Left Ventricular Mass Index to height(LVMI [m²]) Left Atrial Diameter (LAD [mm]) Blood Pressure (mmHg) Body Weight BMI Predialysis TnT postdialysis TnT proBNP Quality of Life | — |
Countries
Austria
Outcome results
None listed